• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·086450.KQ
Share

DongKook Pharmaceutical Co., Ltd. Stocks

₩ 25150Last Updated 13.11.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

₩ 775.52M

₩ 25150
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 086450.KQ is 31987 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

14.11.2026 03:40

Huang still holds $135 billion worth of Nvidia stock. Why is this worrying investors?

14.11.2026 02:56

Nvidia's Worst Week: A $570 Billion Loss and the Most Cautious Analysts in 3 Years

14.11.2026 02:20

Flights have been suspended at all airports in the U.S. This happens extremely rarely.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026